Absorbable coronary stents

Lancet

Volumn 369, Issue 9576, 2007, Pages 1839-1840

  Ormiston, John ^a   Webster, Mark ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; EVEROLIMUS; MAGNESIUM; POLYLACTIC ACID; POLYMER;

ARTICLE; BIODEGRADABLE IMPLANT; CORONARY STENT; DELAYED HYPERSENSITIVITY; HEART INFARCTION; HUMAN; IMAGING SYSTEM; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; SURGICAL TECHNIQUE; THROMBOSIS;

EID: 34249682080     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60829-0     Document Type: Note

References (9)

1. Kotani J.-I., Awata M., Nato S., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (2006) 2108-2111
2. Finn A., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115 (2007) 2435-2441
3. Virmani R., Guagliumi G., Farb A., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
4. Ormiston J., Stewart F., Roche A., Webber B., Whitlock R., and Webster M. Late regression of the dilated site after coronary angioplasty: a five year quantitative angiographic study. Circulation 96 (1997) 468-474
5. Erbel R., Di Mario C., Bartunek J., et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369 (2007) 1869-1875
6. Serruys P., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Eng J Med 331 8 (1994) 489-495
7. Mintz G., Popma J., Pichard A., et al. Arterial remodeling after coronary angioplasty. A serial intravascular ultrasound study. Circulation 94 (1996) 35-43
8. Ormiston J., Webster M., and Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Cathet Cardiovasc Interv 69 (2007) 128-131
9. Dudek D. The ABSORB trial nine month results from the first-in-man evaluation of a fully bioabsorbable everolimus-eluting coronary stent. http://www.europcronline.com/diapos/EuroPCR2007/3788-140-23_20070522_17_55_Room1_Dudek_Dariusz_Speaker/Dariusz_Dudek_ABSORB_22May2007.pdf (accessed May 29, 2007).